Notice of Intent to Sole Source – Oncotype DX Cancer Testing Services
Cancelled Special Notice Posted
- Solicitation number
- HT941026N0123
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Nellis AFB, Nevada 89191, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency Contracting Activity, Healthcare Contracting Division-West, issued a Notice of Intent to Sole Source for Oncotype DX Cancer Testing Services supporting Mike O'Callaghan Military Medical Center, Nellis AFB, Nevada, with a capability statement deadline of 10:00 a.m. Pacific Daylight Time on September 11, 2026. This is a sole-source procurement — not a request for competitive quotations or proposals — though interested sources may submit capability statements to influence the Government's decision on competitive procurement versus sole-source award.
The requirement is for the specific Oncotype DX branded genomic tumor-testing service and associated diagnostic reports for eligible patients. The contractor shall provide specimen submission materials, perform testing at its facility, deliver written test results with clinical interpretation, and return tissue tumor blocks or unstained slides per contract specifications. Period of performance runs from September 16, 2026 through September 15, 2027, with four optional 12-month periods and a potential six-month extension.
Capability statements must not exceed six pages (8.5 x 11-inch paper, 10-point minimum font) and must demonstrate management and technical capabilities including testing performance, results interpretation, specimen materials, and specimen return procedures. Submit as Microsoft Word or PDF attachments to Dominic Gonzales at dominic.n.gonzales.civ@health.mil. No telephone requests or offers will be accepted. NAICS 621511 (Medical Laboratories); PSC Q301 (Reference Laboratory Testing).
Notice text
2 versions
Update #2 · Latest ·
The Defense Health Agency Contracting Activity, Healthcare Contracting Division–West, intends to negotiate and award a firm-fixed-price sole-source contract to EXACT SCIENCES LABORATORIES, LLC for Oncotype DX Cancer Testing Services in support of Mike O’Callaghan Military Medical Center, Nellis AFB, Nevada.
The requirement is for the specific Oncotype DX branded genomic tumor-testing service and associated report for eligible patients. The contractor shall provide materials necessary for specimen submission, perform required testing at the contractor’s facility, provide written test results and interpretation, and return tissue tumor blocks or unstained slides in accordance with the resulting contract.
The anticipated period of performance is 16 September 2026 through 15 September 2027, with four 12-month option periods and a potential six-month extension. This is a Notice of Intent to Sole Source and is not a request for competitive quotations or proposals. Interested sources may submit a capability statement by the response deadline stated in this notice.
Update #1 ·
The Defense Health Agency Contracting Activity, Healthcare Contracting Division–West, intends to negotiate and award a firm-fixed-price sole-source contract to Genomic Health, Inc., an Exact Sciences company, for Oncotype DX Cancer Testing Services in support of Mike O’Callaghan Military Medical Center, Nellis AFB, Nevada.
The requirement is for the specific Oncotype DX branded genomic tumor-testing service and associated report for eligible patients. The contractor shall provide materials necessary for specimen submission, perform required testing at the contractor’s facility, provide written test results and interpretation, and return tissue tumor blocks or unstained slides in accordance with the resulting contract.
The anticipated period of performance is 16 September 2026 through 15 September 2027, with four 12-month option periods and a potential six-month extension. This is a Notice of Intent to Sole Source and is not a request for competitive quotations or proposals. Interested sources may submit a capability statement by the response deadline stated in this notice.
Files
| File | Type | Posted |
|---|---|---|
| HT941026N0123.docx | DOCX document | |
| HT941026N0123.docx | DOCX document |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Q301--NEW – STX Specialized Molecular Residual Disease Testing | Veterans Integrated Service Network 17 | No set-aside | |
| Q301--leptomeningeal and coronary research services. | Veterans Integrated Service Network 22 | No set-aside | |
| Q301--FY27 (BASE+4) STAT Laboratory Testing - Syracuse (VA-27-00010334) | Veterans Integrated Service Network 2 | No set-aside | |
| NOI - DNA Sequencing of Bone Marrow Failure Syndro | Office of Logisitics and Acquisition Operations | No set-aside | |
| Notice of intent to award a sole source | Naval Supply Systems Command | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity